Clinical review report: Dupilumab (Dupixent) (Sanofi genzyme, a division of Sanofi-Aventis Canada Inc.) indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those t...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, June 2020
Edition:	Version: Final
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK565239
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa